Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- ₹527.76 billion
- Book Value:
- Revenue TTM:
- ₹67.57 billion
- Operating Margin TTM:
- Gross Profit TTM:
- ₹43.15 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Biocon Limited had its IPO on under the ticker symbol 532523.
The company operates in the Other sector and Other industry. Biocon Limited has a staff strength of 12,609 employees.
Shares of Biocon Limited opened at ₹276.55 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹265.55 - ₹277.4, and closed at ₹267.
This is a -3.42% slip from the previous day's closing price.
A total volume of 314,524 shares were traded at the close of the day’s session.
In the last one week, shares of Biocon Limited have increased by +2.26%.
Biocon Limited's Key Ratios
Biocon Limited has a market cap of ₹527.76 billion, indicating a price to book ratio of 7.5633 and a price to sales ratio of 7.8273.
In the last 12-months Biocon Limited’s revenue was ₹67.57 billion with a gross profit of ₹43.15 billion and an EBITDA of ₹15.59 billion. The EBITDA ratio measures Biocon Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Biocon Limited’s operating margin was 13.73% while its return on assets stood at 4% with a return of equity of 10.02%.
In Q3, Biocon Limited’s quarterly earnings growth was a negative -22.5% while revenue growth was a positive 11%.
Biocon Limited’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at ₹5.401 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Biocon Limited’s profitability.
Biocon Limited stock is trading at a EV to sales ratio of 8.0291 and a EV to EBITDA ratio of 29.0549. Its price to sales ratio in the trailing 12-months stood at 7.8273.
Biocon Limited stock pays annual dividends of ₹ per share, indicating a yield of 0% and a payout ratio of 8.67%.
Balance sheet and cash flow metrics
- Total Assets
- ₹520.43 billion
- Total Liabilities
- ₹85.11 billion
- Operating Cash Flow
- Capital Expenditure
- ₹17.26 billion
- Dividend Payout Ratio
Biocon Limited ended 2023 with ₹520.43 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹520.43 billion while shareholder equity stood at ₹178.67 billion.
Biocon Limited ended 2023 with ₹0 in deferred long-term liabilities, ₹85.11 billion in other current liabilities, 6003000000.00 in common stock, ₹172.67 billion in retained earnings and ₹161.36 billion in goodwill. Its cash balance stood at ₹0 and cash and short-term investments were ₹38.59 billion. The company’s total short-term debt was ₹0 while long-term debt stood at ₹152.91 billion.
Biocon Limited’s total current assets stands at ₹123.34 billion while long-term investments were ₹0 and short-term investments were ₹14.59 billion. Its net receivables were ₹35.73 billion compared to accounts payable of ₹0 and inventory worth ₹42.44 billion.
In 2023, Biocon Limited's operating cash flow was ₹-142818000000.00 while its capital expenditure stood at ₹17.26 billion.
Comparatively, Biocon Limited paid ₹0.09 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Biocon Limited stock is currently trading at ₹267 per share. It touched a 52-week high of ₹308.5073 and a 52-week low of ₹308.5073. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹259.84 and 200-day moving average was ₹245.39 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6590.5% of the company’s stock are held by insiders while 1321.8% are held by institutions.
Frequently Asked Questions About Biocon Limited
Similar Industry Stocks (Other)
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Small Molecules, Biologics, Branded Formulations, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology, and inflammatory diseases. The company provides biosimilars comprising recombinant human insulin, insulin glargine, biosimilar trastuzumab, and other biopharmaceuticals; small molecules, such as active pharmaceutical ingredients and generic formulations; and branded formulation products under the Insugen, Basalog, BIOMAb EGFR, CANMAb, and ALZUMAb brands. It is also involved in the integrated discovery, development, and manufacturing services for small and large molecules, antibody-drug conjugates, and oligonucleotides. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.